Altogether, these results indicate that osteoprotegerin plays a controversial role in bone metastases: while a large set of experimental data supports its osteoclast- and hence tumor-inhibiting role, in certain situations osteoprotegerin is documented to stimulate osteolysis and tumor growth. This evidence concerns the gene TNFRSF11B and neoplasm.